Evaluate the Efficacy and Safety of N02RS1 in Patient With Acute Bronchitis
NCT ID: NCT02637310
Last Updated: 2016-03-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
108 participants
INTERVENTIONAL
2015-12-31
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Assess the Effectiveness and Safety of GSK3862995B in Adults With Bronchiectasis
NCT07201051
To Evaluate the Efficacy and Safety of ALC-2203 in Patients With Acute Bronchitis
NCT07061925
Efficacy and Safety of AG2001 in Patients With Acute Bronchitis
NCT07198347
A Clinical Study of RSS0343 in Healthy Subjects
NCT07289464
Study of Expectorant Activity of Oral N-acetylcystein (NAC) in Patients With Stable Chronic Bronchitis
NCT00205647
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
N02RS1 1200mg
Combination of Broussonetia spp and Lonicera spp
N02RS1 1200mg
1200mg/day, Three times a day orally, 2 tablets once, 7 days
Placebo
sugar pill
Placebo
1200mg/day, Three times a day orally, 2 tablets once, 7 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
N02RS1 1200mg
1200mg/day, Three times a day orally, 2 tablets once, 7 days
Placebo
1200mg/day, Three times a day orally, 2 tablets once, 7 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients acute bronchitis, sputum symptoms, BSS over 7 points.
* Patients acute bronchitis within 7days.
* Non-pregnant, patients who agree to contraception.
* Patients who can write diary and available to communicate.
* Patients voluntarily agreed
Exclusion Criteria
* Patients who have gotten systemic steroid treatment within 4 weeks.
* Patients who have gotten treatment of antibiotics, bronchodilators, painkiller and secretagog within 7 days.
* Patients who have gotten treatment of mucus solvents or antitussives within 3 days.
* Patients who serious respiratory infections requiring antibiotic treatment, allergic bronchial asthma, bronchiectasis and chronic obstructive pulmonary disease.
* Patients heart disease, severe kidney, liver disease.
* The bleeding tendency or immunosuppressed patients.
* Patients with clinically significant abnormal values.
* Pregnant women or nursing mothers.
* Patients alcoholics or drug abuse.
* Patients taking other clinical trail's medicines within 30 days.
19 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
PharmaKing
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PMK-N02RS1_Phase 2B
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.